Corcept Therapeutics is trading 4.09% up now at $117.56 after the EMA’s CHMP recommended European approval of relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer. - The recommendation followed positive Phase 2 and Phase 3 ROSELLA results showing improved progression-free and overall survival. - The European Commission is expected to make a final decision during the fourth quarter of 2026. - Biotechnology weakness and elevated Treasury yields are partially offsetting the company-specific catalyst.